CapsazepineTRPV1 ion channel activator |
Sample solution is provided at 25 µL, 10mM.
Quality Control & MSDS
- View current batch:
- Purity = 98.02%
- COA (Certificate Of Analysis)
- HPLC
- NMR (Nuclear Magnetic Resonance)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
Capsazepine Dilution Calculator
calculate
Capsazepine Molarity Calculator
calculate
Cas No. | 138977-28-3 | SDF | Download SDF |
Chemical Name | N-[2-(4-chlorophenyl)ethyl]-7,8-dihydroxy-1,3,4,5-tetrahydro-2-benzazepine-2-carbothioamide | ||
Canonical SMILES | C1CC2=CC(=C(C=C2CN(C1)C(=S)NCCC3=CC=C(C=C3)Cl)O)O | ||
Formula | C19H21ClN2O2S | M.Wt | 376.9 |
Solubility | ≥22 mg/mL in DMSO with gentle warming, ≥18.85 mg/mL in EtOH with gentle warming, <2.58 mg/ml="" in="" h2o="">2.58> | Storage | Store at -20°C |
Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. |
Capsazepine is a competitive antagonist of vanilloid (capsaicin) receptor with IC50 value of 562 nM.[1]
Capsazepine is a synthetic analogue of capsaicin, which activates the TRPV1 ion channel, thereby, blocks the painful sensation of heat caused by capsaicin. Capsazepine blocked voltage-activated calcium currents in adult rat dorsal root ganglion neurons with EC50 value of 7.7±1.4 μM.[2] Capsazepine was also able to block the response of TRPM8 to menthol (IC50=18±1.1 μM).[3] Capsazepine also inhibited nicotinic acetylcholine receptors in rat trigeminal ganglia at 10μM.[4] In human colon cancer cells, capsazepine treatment activated caspase -8, –9, and -3, induced death receptors (DRs) DR5 and DR4, then sensitized the cells to TRAIL-induced apoptosis.[5] Capsazepine is thought to be a tool to study the TRPV1 ion channel.
References:1.C. S. Walpole, S. Bevan, G. Bovermann, J. J. Boelsterli, R. Breckenridge, J. W. Davies, G. A. Hughes, I. James, L. Oberer, J. Winter and et al., J Med Chem 1994, 37, 1942-1954. 2.R. J. Docherty, J. C. Yeats and A. S. Piper, Br J Pharmacol 1997, 121, 1461-1467. 3.H. J. Behrendt, T. Germann, C. Gillen, H. Hatt and R. Jostock, Br J Pharmacol 2004, 141, 737-745. 4.L. Liu and S. A. Simon, Neurosci Lett 1997, 228, 29-32. 5.B. Sung, S. Prasad, J. Ravindran, V. R. Yadav and B. B. Aggarwal, Free Radic Biol Med 2012, 53, 1977-1987.